Development of anticancer agents : wizardry with osmium

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review

127 Scopus Citations
View graph of relations

Author(s)

Detail(s)

Original languageEnglish
Pages (from-to)1640-1648
Journal / PublicationDrug Discovery Today
Volume19
Issue number10
Online published21 Jun 2014
Publication statusPublished - Oct 2014
Externally publishedYes

Abstract

Platinum compounds are one of the pillars of modern cancer chemotherapy. The apparent disadvantages of existing chemotherapeutics have led to the development of novel anticancer agents with alternative modes of action. Many complexes of the heavy metal osmium (Os) are potent growth inhibitors of human cancer cells and are active in vivo, often superior or comparable to cisplatin, as the benchmark metal-based anticancer agent, or clinically tested ruthenium (Ru) drug candidates. Depending on the choice of ligand system, osmium compounds exhibit diverse modes of action, including redox activation, DNA targeting or inhibition of protein kinases. In this review, we highlight recent advances in the development of osmium anticancer drug candidates and discuss their cellular mechanisms of action.

Citation Format(s)

Development of anticancer agents: wizardry with osmium. / Hanif, Muhammad; Babak, Maria V.; Hartinger, Christian G.
In: Drug Discovery Today, Vol. 19, No. 10, 10.2014, p. 1640-1648.

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review